|
The prognostic value of tumor residuals indicated by surgeon, by radiology or an integrated approach by surgeons' assessment and pre-chemotherapy CT-scan in patients with advanced ovarian cancer: An exploratory analysis of the AGO Study led Intergroup trial AGO-OVAR 12. |
|
|
Consulting or Advisory Role - AstraZeneca; Roche |
Speakers' Bureau - AstraZeneca; Roche |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Honoraria - AstraZeneca; Roche |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; PharmaMar; Roche; Sotio; Tesaro |
Travel, Accommodations, Expenses - Medac |
|
Elisabeth Avall-Lundqvist |
|
Consulting or Advisory Role - AstraZeneca |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Amgen; AstraZeneca; Clovis Oncology; MSD Oncology; Pfizer; PharmaMar; Roche/Genentech |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Amgen (Inst); Array Biopharma (Inst); AstraZeneca (Inst); Biogen (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Endocyte (Inst); Fresenius (Inst); GE Healthcare (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Hampton Medical Conferences (Inst); Intuitive Surgical (Inst); Janssen-Cilag (Inst); Kendle (Inst); Lilly (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Morphotek (Inst); Nektar (Inst); Novo Nordisk (Inst); Oasmia Pharmaceutical AB (Inst); PharmaMar (Inst); Phillips Gilmore Oncology (Inst); Quintiles (Inst); Roche (Inst); Sanofi (Inst); Schering-Plough (Inst); Sigma-Tau (Inst); Telik (Inst); TRM Oncology (Inst) |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Eisai (Inst); Exelixis (Inst); Fresenius Biotech (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Janssen-Cilag (Inst); Merck Sharp & Dohme (Inst); Merrimack (Inst); Morphotek (Inst); Nektar (Inst); Nerviano Medical Sciences (Inst); Novartis (Inst); Pfizer (Inst); Proacta (Inst); Quintiles (Inst); Roche (Inst); Sandoz (Inst); Sanofi (Inst); Schering-Plough (Inst); Vifor Pharma (Inst); Wyeth (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; GCI Health; Oasmia Pharmaceutical AB; PharmaMar; Roche |
|
|
Consulting or Advisory Role - AstraZeneca; Immunogen; Novartis; Roche |
Travel, Accommodations, Expenses - PharmaMar |
|
|
Consulting or Advisory Role - MSD |
Research Funding - PharmaMar |
Travel, Accommodations, Expenses - Novartis |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Novartis; PharmaMar; Roche (I); Sanofi |
Consulting or Advisory Role - Novartis; Roche |
Travel, Accommodations, Expenses - Bayer; Novartis |
|
|
Honoraria - AstraZeneca; Roche |
Consulting or Advisory Role - Roche |
|
|
Honoraria - AstraZeneca; PharmaMar; Roche; Tesaro |
Consulting or Advisory Role - AstraZeneca; Clovis Oncology; Novogene; Roche; Tesaro |
Research Funding - Amgen; Bayer; Lilly; Novartis |
|
|
|
Consulting or Advisory Role - Tesaro |
|
|
Research Funding - Ergomed (Inst); MANGO (Inst) |
|
|
Employment - Boehringer Ingelheim |
Honoraria - Boehringer Ingelheim |
|
|
Consulting or Advisory Role - AstraZeneca; Mundipharma; Pfizer; Pharmamar; Roche/Genentech |